Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2020-06-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the project is to characterize and validate the salivary Raman fingerprint of COVID-19, understanding the principal biomolecules involved in the differences between the three experimental groups: 1) healthy subjects, 2) COVID-19 patients and 3) subjects with a past infection by COVID-19. The large amount of Raman data will be used to create a salivary Raman database, associating each data with the relative clinical data collected.
Starting from the preliminary results and protocols of the Laboratory of Nanomedicine and Clinical Biophotonics (LABION) - IRCCS Fondazione Don Gnocchi Milano, the saliva collected from each experimental group will be analysed using Raman spectroscopy. All the data will be processed for the baseline, shift and normalization in order to homogenize the signals collected and creating in this way the Raman database. The average spectrum calculated from each group will be characterized, identifying the principal families of biological molecules responsible for the spectral differences.
EXPECTED RESULTS: Verify the possibility to use Raman spectroscopy on saliva samples for the identification of subjects affected by COVID-19. The principal aim of the project is to create a classification model able to: discriminate COVID-19 current and past infection, identify the principal biological molecules altered in saliva during the infection, predict the clinical course of newly diagnosed COVID-19 patients, translation and application of the classification model to a portable Raman for the test of a point of care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Saliva for COVID-19 Diagnosis
NCT04953039
SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling
NCT04460638
Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic
NCT04367545
Biomarkers in Saliva and Stool
NCT03297008
Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects
NCT04547114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVES: The aim of the project is to characterize and validate the salivary Raman fingerprint of COVID-19, understanding the principal biomolecules involved in the differences between the three experimental groups: 1) healthy subjects, 2) COVID-19 patients and 3) subjects with a past infection by COVID-19. The large amount of Raman data will be used to create a salivary Raman database, associating each data with the relative clinical data collected. The Raman database will be used for the creation of a classification model through the application of multivariate analysis in terms of principal component analysis and linear discriminant analysis. This classification model will provide a fast tool for the discrimination of the COVID-19 condition, potentially providing also information on the respiratory clinical course of the patient. The model will be translated for the application to a portable Raman spectrometer, leading to the creation of a Raman Point of Care METHODS: Starting from the preliminary results and protocols of the Laboratory of Nanomedicine and Clinical Biophotonics (LABION) - IRCCS Fondazione Don Gnocchi Milano, the saliva collected from each experimental group will be analysed using Raman spectroscopy. All the data will be processed for the baseline, shift and normalization in order to homogenize the signals collected and creating in this way the Raman database. The average spectrum calculated from each group will be characterized, identifying the principal families of biological molecules responsible for the spectral differences. Consecutively, all the spectra will be processed through multivariate analysis (principal component analysis and linear discriminant analysis) obtaining in this way the classification model. LOOCV will be used for the training of the classification model, which will be questioned using the subset validation analysis. The partial correlation coefficient (Pearson's and Spearman's correlation) will be used for the Raman correlation with the clinical parameter (e.g. COVID-19 clinical course) using as control covariates the age and sex of the subjects. The classification model will be then translated and used as point of care using a portable Raman equipped with a laser emitting at 785 nm, with a comparable spectral resolution.
* SAMPLE COLLECTION: Saliva will be collected with Salivette (SARSTEDT, Germany), following the manufacturer's instructions. The cotton swab will be inserted in the subject mouth and chewed for 60 seconds. The saliva collection will be achieved through centrifugation of the swab (1000 g x 2 min), recording all the related parameters (storage temperature and the time between collection and analysis). All the collection procedures will be performed at least two hours after the last meal and teeth brushing.
* SAMPLE PROCESSING: Before the analysis, saliva (3 ul) will be deposited on aluminum foil and dried overnight. The aluminum foil is fundamental to achieve the Surface Enhanced Raman Scattering, increasing the saliva Raman signal.
* DATA COLLECTION: Raman spectra will be acquired using an Aramis Raman microscope (Horiba Jobin-Yvon, France) equipped with a laser light source operating at 785 nm with 100% (512mW) laser power. Acquisition time will be set at 30 seconds with double acquisition and 2 seconds delay time to prevent the formation of artifact spectra. Before each analysis, the instrument will be calibrated using the reference band of silicon. All the signals will be acquired in the region between 400 and 1600 cm-1 with a resolution of 0.8cm-1, acquiring at least 25 spectra following a square-map. The software package LabSpec 6 (Horiba Jobin-Yvon) will be used for map design and the acquisition of spectra.
* DATA ANALYSIS: All the data will be fit using a fourth-degree polynomial curve to set the baseline and consecutively normalized using unit vector. The contribution of aluminum will be removed from each spectrum. The statistical analysis will be performed using the multivariate approach. Briefly, principal component analysis and linear discriminant analysis will be applied to extract the principal components and the canonical variables. These features will be used for the leave one out cross-validation (LOOCV), subset validation and correlation with the clinical parameters. Mann-Whitney will be performed on PCs scores to verify the differences statistically relevant between the analysed groups. The analysis will be performed using Origin software (OriginLab, USA)
* CORRELATION: Partial correlation with Pearson's and Spearman's coefficients will be performed on the variables extracted and the clinical parameters, using as control covariates the age and sex of the subjects. Only values with p \< 0.001 will be considered as statistically relevant.
* TRANSLATION: The data and the classification model will be applied with a portable Raman equipped with a laser emitting at 785 nm and with a spectral resolution comparable with the one used for the previous analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Subjects
40 Healthy Subjects in a good state of health comparable by age and sex with the other selected groups and with a negative test for SARS-CoV-2 or collected before the pandemic event
Raman analysis of saliva, characterization of the Raman database and building of the classification model
Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
COVID-19 Positive
40 subjects affected by COVID-19, determined by positive nasopharyngeal test for SARS-CoV-2 and with comparable age and sex for the other selected groups
Raman analysis of saliva, characterization of the Raman database and building of the classification model
Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
COVID-19 Negative
40 subjects with a past infection by SARS-CoV-2 confirmed and with at least two consecutive negative tests determined by nasopharyngeal SARS-CoV-2 assay, comparable by age and sex with the other selected groups
Raman analysis of saliva, characterization of the Raman database and building of the classification model
Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Raman analysis of saliva, characterization of the Raman database and building of the classification model
Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provided written consent for the salivary analysis
* Age between 18 and 90 years
Exclusion Criteria
* Age lower than 18 and higher than 90 years
* No written consent provided
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Don Carlo Gnocchi Onlus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marzia Bedoni, PhD
Role: STUDY_CHAIR
IRCCS Fondazione Don Carlo Gnocchi, Laboratory of Nanomedicine and Clinical Biophotonics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliera Universitaria Policlinico di Bari
Bari, Apulia, Italy
Fondazione Don Carlo Gnocchi, Centro Spalenza
Rovato, BS, Italy
IRCCS Fondazione Don Carlo Gnocchi, Santa Maria Nascente Hospital (Milano)
Milan, MI, Italy
Farmaacquisition srl
Milan, , Italy
Università degli Studi di Milano-Bicocca
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X, Li J, Duan J, Yan Z, Yang M, Tan H, Ma M, Li T, Yi D, Mi Z, Zhao H, Jiang Y, He Z, Li H, Nie W, Liu Y, Zhao J, Luo M, Liu X, Rong P, Wang W. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun. 2020 Oct 2;11(1):4968. doi: 10.1038/s41467-020-18786-x.
Carlomagno C, Cabinio M, Picciolini S, Gualerzi A, Baglio F, Bedoni M. SERS-based biosensor for Alzheimer disease evaluation through the fast analysis of human serum. J Biophotonics. 2020 Mar;13(3):e201960033. doi: 10.1002/jbio.201960033. Epub 2020 Jan 1.
Carlomagno C, Banfi PI, Gualerzi A, Picciolini S, Volpato E, Meloni M, Lax A, Colombo E, Ticozzi N, Verde F, Silani V, Bedoni M. Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis. Sci Rep. 2020 Jun 23;10(1):10175. doi: 10.1038/s41598-020-67138-8.
Gualerzi A, Niada S, Giannasi C, Picciolini S, Morasso C, Vanna R, Rossella V, Masserini M, Bedoni M, Ciceri F, Bernardo ME, Brini AT, Gramatica F. Raman spectroscopy uncovers biochemical tissue-related features of extracellular vesicles from mesenchymal stromal cells. Sci Rep. 2017 Aug 29;7(1):9820. doi: 10.1038/s41598-017-10448-1.
Related Links
Access external resources that provide additional context or updates about the study.
Laboratory of Nanomedicine and Clinical Biophotonics at IRCCS Fondazione Don Carlo Gnocchi ONLUS, Milano (Italy)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FDG_SalivaCOVID01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.